News & events

News & events

Filter by:
  • NewsScientific publications

VarmX announces publication of non-clinical safety, toxicokinetic and pharmacodynamic data for VMX-C001 in Pharmaceutics

Key Highlights The peer-reviewed study, published in Pharmaceutics (MDPI), describes the non-clinical safety pharmacology, toxicokinetics and pharmacodynamics of VMX-C001 in...

  • News

VarmX announces reltodecacog alfa (Relto) as the adopted non-proprietary name for VMX-C001

Adopted USAN: Reltodecacog alfa has been adopted by the United States Adopted Names (USAN) Council as the non-proprietary name for...

  • News

VarmX raises € 12.5 million to develop VMX-COO1

VarmX, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis, today announced...
  • News

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

VarmX announces publication in Nature Communications of groundbreaking snake venom inspired approach to restore blood clotting in patients using anticoagulants...
  • Scientific publications

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors

The absence of an adequate reversal strategy to prevent and stop potential life-threatening bleeding complications is a major drawback to...

  • News

VarmX raises seed capital for development of VMX-C001

VarmX, a Dutch, Leiden based biotech company focusing on the development of therapies in the field of hemostasis and thrombosis,...

VMX-C001: Transforming the treatment of bleeding in patients taking Factor Xa DOACs

Portfolio